Medical uses:

Skytrofa is a human growth hormone designed for pediatric patients aged 12 months and older, weighing at least 11.5 kg (26 pounds), who experience growth failure due to insufficient secretion of endogenous growth hormone (GH).

Recommended Dosage: Skytrofa should be administered subcutaneously into the buttock, abdomen, or thigh, with regular rotation of injection sites. The recommended dose is 0.24 mg/kg of body weight, given once weekly.

If a dose is missed, it should be administered as soon as possible, but no later than two days after the missed dose. To prevent missed doses, Skytrofa can be taken up to two days before or after the scheduled dosing day. Weekly dosing should then continue on the originally scheduled day.

Warnings & Precautions:

ncreased mortality has been observed in patients with acute severe illness following complications from abdominal surgery, open heart surgery, multiple accidental traumas, or acute respiratory failure when treated with somatropin.

Serious systemic hypersensitivity reactions, including those from Skytrofa injections, may occur. Immediate medical attention is required if any allergic reactions are suspected.

There is a risk of malignancy progression in patients undergoing somatropin therapy with active malignancy. Preexisting malignancies must be inactive and treated before starting Skytrofa therapy. Discontinue treatment if there is evidence of recurrent malignancy.

Patients with a history of growth hormone deficiency due to an intracranial neoplasm should be monitored throughout somatropin treatment for tumor recurrence or growth.

Regular assessments are necessary for patients on somatropin therapy to detect enhanced growth or potential malignant changes in preexisting nevi. Patients should report any significant changes in behavior, vision, skin pigmentation, headaches, or preexisting nevi.

Somatropin therapy may reduce insulin sensitivity, especially at higher doses. Monitor glucose levels in all patients receiving Skytrofa, particularly those with risk factors for type-2 diabetes mellitus, such as obesity or a family history of the condition.

Cases of slipped capital femoral epiphysis have been frequently reported in patients experiencing rapid growth. Pediatric patients with persistent hip or knee pain should be evaluated.

Parathyroid hormone, alkaline phosphatase, and serum levels of phosphate may increase after therapy with somatropin. In case a patient is detected to have no normal laboratory outcomes, evaluate as required. 

Documentation & Availability :

Documents  required to import SKYTROFA  to India?

SKYTROFA (lonapegsomatropin-tcgd) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:

2 ID proofs along with PAN card details along with attested scanned copies

Valid doctor prescription scanned copy

Doctor’s MCI number

Doctor’s mobile number

Patients diagnostic reports

How is the order confirmed?

The order will be confirmed only after the receipt of:

The above-mentioned documents and drug availability.

Import permit if applicable.

Sourcing & Delivery:

The Rx4U team has extensive experience in sourcing SKYTROFA (Cancer Treatment Medicines)  from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.

 FAQ:

What is the Generic Name for the trade name drug Skytrofa®?

Lonapegsomatropin-tcgd is a Generic Name for the trade name drug Skytrofa®.

What is the Manufacturer’s Name of Skytrofa®?

Skytrofa® is manufactured by Ascendis Pharma. 

Is Skytrofa® approved by the FDA?

Yes, Skytrofa® is approved by the FDA. Date of first approval: August 25, 2021.

Where can I get Skytrofa 3.6 mg at the best price in India?

To get the best Skytrofa 3.6 mg price in India, kindly get in touch with Rx4u team.

What is the dosage and form of Skytrofa® supplied?

Skytrofa® is supplied as injections: 3mg, 3.6mg, 4.3mg, 5.2mg, 6.3mg, 7.6mg, 9.1mg, 11mg, and 13.3mg for subcutaneous administration. 

What are the most common side effects of Skytrofa®? 

The most common side effects of Skytrofa are nausea and vomiting, viral infection, pyrexia, hemorrhage, cough, diarrhea, abdominal pain, and arthralgia and arthritis

How much does Skytrofa cost in India?

The skytrofa cost in India can vary. In order to procure this human growth hormone authentically, you can reach out to Rx4u team.

What are the storage conditions of Skytrofa®?

Cartridges of Skytrofa should be refrigeratd at 36-46°F (2-8°C) in the outer carton in order to protect from light. It is not advisable to freeze this medicine.

Is it safe to buy Skytrofa® online from India?

Yes, one can buy Skytrofa from India at the best price from www.rx4u.in.

*Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.